# China NMPA Drug Inspection - Beijing Linshengtang Pharmaceutical Co., Ltd. - Weiling Granules

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/beijing-linshengtang-pharmaceutical-co-ltd/756cf6ad-51c0-4ee5-bd1e-2e99a23d600c
Source feed: China

> China NMPA drug inspection for Beijing Linshengtang Pharmaceutical Co., Ltd. published July 19, 2018. Drug: Weiling Granules. The Beijing Municipal Food and Drug Administration (BMFDA) released an announcement on July 19, 2018, detailing the outc

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement of Beijing Municipal Food and Drug Administration on Drug Quality and Safety in the Second Quarter of 2018
- Company Name: Beijing Linshengtang Pharmaceutical Co., Ltd.
- Publication Date: 2018-07-19
- Drug Name: Weiling Granules
- Inspection Finding: examine
- Action Taken: The matter will be investigated and dealt with in accordance with the "Drug Administration Law of the People's Republic of China" and other relevant regulations, and follow-up sampling and testing will be conducted within the jurisdiction as appropriate.
- Summary: The Beijing Municipal Food and Drug Administration (BMFDA) released an announcement on July 19, 2018, detailing the outcomes of its drug supervision and sampling inspections conducted during the second quarter of 2018 (April-June). These inspections, part of the 2018 Beijing Municipal Food and Drug Administration Food and Drug Safety Monitoring Plan, aimed to assess drug quality across production, operation, and use within the city.

Out of 1849 drug batches tested, two were identified as substandard. One such instance involved Xinnaoxin Tablets (Batch No. 3971101) manufactured by Beijing Haiderun Pharmaceutical Group Co., Ltd., which failed to meet the specified 'weight per tablet' standard (National Food and Drug Administration Standard YBZ13882009). The other concerned Weiling Granules (Batch No. 170401), produced by Siping Zhenghe Pharmaceutical Co., Ltd., which was found to be substandard against the 'Ministry of Health Drug Standards' Traditional Chinese Medicine Compound Preparations Volume VI. Beijing Linshengtang Pharmaceutical Co., Ltd. was the sampling unit for the latter product.

In response to these findings, the BMFDA will investigate and handle the identified issues in accordance with the 'Drug Administration Law of the People's Republic of China' and other relevant regulations. The administration also committed to conducting necessary follow-up sampling inspections within its jurisdiction to ensure ongoing compliance and public health.

Company: https://www.globalkeysolutions.net/companies/beijing-linshengtang-pharmaceutical-co-ltd/f1f17adb-61a5-4014-9c18-dbed4d2eac01